This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library



MASAC Recommendation #180

View Printer-Friendly PDF Version >>



The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on April 17, 2008, and adopted by the NHF Board of Directors on June 15, 2008.


In 2007, the National Heart, Lung, and Blood Diseases Institute (NHLBI) of the National Institutes of Health (NIH) convened a consensus panel of experts in the field of hemostasis disorders to develop a document summarizing the current body of knowledge regarding the diagnosis and treatment of individuals with von Willebrand disease.  That document has now been published as The Diagnosis, Evaluation and Management of von Willebrand Disease.


This publication is an excellent summary of current knowledge of this disorder, especially because it rates the knowledge by level of evidence.  The panel and the NHLBI are to be commended for the comprehensive approach to diagnosis and management detailed in the document, as well as the extensive list of references.


In the document, the panel outlines areas where more work needs to be done, specifically to develop better tests to improve the ability to diagnose VWD, and highlights the need to train more specialists in the diagnosis and treatment of von Willebrand disease and other bleeding disorders. Thus MASAC recommends that federal funding agencies and manufacturers of clotting factor replacement therapies support research aimed at improving the ability to accurately diagnose VWD and develop initiatives that will lead to the training of more hematologists knowledgeable in the diagnosis and management of hemostatic disorders.



  1. The Diagnosis, Evaluation and Management of von Willebrand Disease, National Heart, Lung, and Blood Institute, National Institutes of Health (GPO #08-5832). Available at or from the NHLBI Health Information Center, Bethesda, MD (tel. 301-592-8573).
  2. von Willebrand Disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).  Haemophilia 2008; 14: 171-232.

This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.


Copyright 2008 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at